{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:09:47Z","timestamp":1784070587909,"version":"3.55.0"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R33AG61456"],"award-info":[{"award-number":["R33AG61456"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG072301"],"award-info":[{"award-number":["R01AG072301"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R37AG13925"],"award-info":[{"award-number":["R37AG13925"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P01 AG062413"],"award-info":[{"award-number":["P01 AG062413"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AG086085"],"award-info":[{"award-number":["R01 AG086085"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bisphosphonates (BPs) have been used effectively to treat excessive bone loss for over 50 years. Recent clinical evidence suggests extra-skeletal benefits but how this occurs remains unknown. Here we use a panel of human, murine and cellular assessments to chart BP-induced ageing-related changes both systemically and at local organ sites. In vivo spatial transcriptomics in aged mice treated with zoledronate showed a shift in cellular composition towards that of young animals specifically in heart, liver and intestine, with upregulation of genes governing detoxification, mitochondrial stability, energy metabolism, and antioxidation. A 5000-plex randomized trial based human proteomic analysis showed significant alterations in ~400 proteins after zoledronate treatment, with downregulation of proteins linked to genomic instability, proteostasis loss, mitochondrial dysfunction, stem cell exhaustion, and SASPs. Fluorescent labeling and tracing confirmed uptake of bisphosphonates by non-skeletal cells. In addition, low doses of several common, clinically utilized BPs stimulated growth and protected against DNA damage-induced senescence in multiple human cell types, with strongest effects in cardiomyocytes. Finally, proteome-wide target deconvolution with AlphaFold identified previously unrecognized binding partners, including PHB2 and ASAH1, and downstream upregulation of MEF2A was validated to be a key mediator of zoledronate triggered benefits in cardiomyocytes. Collectively, these results identify potential geroprotective mechanisms for BP action in multiple non-skeletal tissues.<\/jats:p>","DOI":"10.1038\/s41392-026-02799-x","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:01:12Z","timestamp":1784070072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiomic profiling of responses to clinical and novel bisphosphonates reveals extraskeletal effects on ageing related signatures"],"prefix":"10.1038","volume":"11","author":[{"given":"Jinsen","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasa Rao","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Knowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1032-1641","authenticated-orcid":false,"given":"Haoqun","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Gamez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy R.","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany-Jayne","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5839-1150","authenticated-orcid":false,"given":"Gayle","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1103-5300","authenticated-orcid":false,"given":"Kilian V. M.","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig G.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iolanda","family":"Vendrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darragh P.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian R.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chas","family":"Bountra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1676-4905","authenticated-orcid":false,"given":"James L.","family":"Kirkland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2936-4372","authenticated-orcid":false,"given":"Sundeep","family":"Khosla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank H.","family":"Ebetino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Roldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Graham G.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"2799_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2022.11.001","volume":"186","author":"C L\u00f3pez-Ot\u00edn","year":"2023","unstructured":"L\u00f3pez-Ot\u00edn, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. Hallmarks of aging: An expanding universe. Cell 186, 243\u2013278 (2023).","journal-title":"Cell"},{"key":"2799_CR2","doi-asserted-by":"publisher","first-page":"e1481","DOI":"10.1210\/clinem\/dgaa728","volume":"106","author":"T Tchkonia","year":"2021","unstructured":"Tchkonia, T., Palmer, A. K. & Kirkland, J. L. New Horizons: Novel Approaches to Enhance Healthspan Through Targeting Cellular Senescence and Related Aging Mechanisms. J. Clin. Endocrinol. Metab. 106, e1481\u2013e1487 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2799_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","volume":"49","author":"RGG Russell","year":"2011","unstructured":"Russell, R. G. G. Bisphosphonates: The first 40 years. Bone 49, 2\u201319 (2011).","journal-title":"Bone"},{"key":"2799_CR4","doi-asserted-by":"publisher","first-page":"115566","DOI":"10.1016\/j.bone.2020.115566","volume":"141","author":"JR Center","year":"2020","unstructured":"Center, J. R., Lyles, K. W. & Bliuc, D. Bisphosphonates and lifespan. Bone 141, 115566 (2020).","journal-title":"Bone"},{"key":"2799_CR5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/s12276-024-01157-7","volume":"56","author":"N Takegahara","year":"2024","unstructured":"Takegahara, N., Kim, H. & Choi, Y. Unraveling the intricacies of osteoclast differentiation and maturation: insight into novel therapeutic strategies for bone-destructive diseases. Exp. Mol. Med. 56, 264\u2013272 (2024).","journal-title":"Exp. Mol. Med."},{"key":"2799_CR6","doi-asserted-by":"publisher","first-page":"115715","DOI":"10.1016\/j.bone.2020.115715","volume":"143","author":"E McCloskey","year":"2021","unstructured":"McCloskey, E., Paterson, A. H., Powles, T. & Kanis, J. A. Clodronate. Bone 143, 115715 (2021).","journal-title":"Bone"},{"key":"2799_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115222","volume":"134","author":"NB Watts","year":"2020","unstructured":"Watts, N. B. et al. History of etidronate. Bone 134, 115222 (2020).","journal-title":"Bone"},{"key":"2799_CR8","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1359\/jbmr.060118","volume":"21","author":"JE Dunford","year":"2006","unstructured":"Dunford, J. E., Rogers, M. J., Ebetino, F. H., Phipps, R. J. & Coxon, F. P. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J. Bone Miner. Res. 21, 684\u2013694 (2006).","journal-title":"J. Bone Miner. Res."},{"key":"2799_CR9","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1172\/JCI0217051","volume":"110","author":"R Lindsay","year":"2002","unstructured":"Lindsay, R. Modeling the benefits of pamidronate in children with osteogenesis imperfecta. J. Clin. Invest. 110, 1239\u20131241 (2002).","journal-title":"J. Clin. Invest."},{"key":"2799_CR10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.bone.2010.08.011","volume":"49","author":"LI Plotkin","year":"2011","unstructured":"Plotkin, L. I., Bivi, N. & Bellido, T. A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice. Bone 49, 122\u2013127 (2011).","journal-title":"Bone"},{"key":"2799_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115390","volume":"137","author":"IR Reid","year":"2020","unstructured":"Reid, I. R. et al. Zoledronate. Bone 137, 115390 (2020).","journal-title":"Bone"},{"key":"2799_CR12","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/jbmr.3138","volume":"32","author":"MA Lawson","year":"2017","unstructured":"Lawson, M. A. et al. The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-\u03b1]Pyridin-3-yl)-Ethyl-Bisphosphonate). J. Bone Miner. Res. 32, 1860\u20131869 (2017).","journal-title":"J. Bone Miner. Res."},{"key":"2799_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/jbmr.4434","volume":"37","author":"DM Black","year":"2022","unstructured":"Black, D. M. et al. The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial. J. Bone Miner. Res. 37, 21\u201328 (2022).","journal-title":"J. Bone Miner. Res."},{"key":"2799_CR14","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles, K. W. et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med. 357, 1799\u20131809 (2007).","journal-title":"N. Engl. J. Med."},{"key":"2799_CR15","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1111\/j.1582-4934.2009.00926.x","volume":"14","author":"M Coscia","year":"2010","unstructured":"Coscia, M. et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J. Cell. Mol. Med. 14, 2803\u20132815 (2010).","journal-title":"J. Cell. Mol. Med."},{"key":"2799_CR16","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s00262-017-2011-1","volume":"66","author":"DW Fowler","year":"2017","unstructured":"Fowler, D. W., Copier, J., Dalgleish, A. G. & Bodman-Smith, M. D. Zoledronic acid renders human M1 and M2 macrophages susceptible to V\u03b42(+) \u03b3\u03b4 T cell cytotoxicity in a perforin-dependent manner. Cancer Immunol. Immunother. 66, 1205\u20131215 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"2799_CR17","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/cas.13491","volume":"109","author":"Y Tanaka","year":"2018","unstructured":"Tanaka, Y. et al. Expansion of human \u03b3\u03b4 T cells for adoptive immunotherapy using a bisphosphonate prodrug. Cancer Sci. 109, 587\u2013599 (2018).","journal-title":"Cancer Sci."},{"key":"2799_CR18","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2217\/fon.11.113","volume":"7","author":"S Metcalf","year":"2011","unstructured":"Metcalf, S., Pandha, H. S. & Morgan, R. Antiangiogenic effects of zoledronate on cancer neovasculature. Future Oncol. 7, 1325\u20131333 (2011).","journal-title":"Future Oncol."},{"key":"2799_CR19","doi-asserted-by":"publisher","first-page":"e36620","DOI":"10.7554\/eLife.36620","volume":"10","author":"Z Yu","year":"2018","unstructured":"Yu, Z. et al. Identification of a transporter complex responsible for the cytosolic entry of nitrogen-containing bisphosphonates. eLife 10, e36620 (2018).","journal-title":"eLife"},{"key":"2799_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41580-020-00314-w","volume":"22","author":"R Di Micco","year":"2021","unstructured":"Di Micco, R., Krizhanovsky, V., Baker, D. & d\u2019Adda di Fagagna, F. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat. Rev. Mol. Cell Biol. 22, 75\u201395 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2799_CR21","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41586-021-03307-7","volume":"592","author":"B Schumacher","year":"2021","unstructured":"Schumacher, B., Pothof, J., Vijg, J. & Hoeijmakers, J. H. J. The central role of DNA damage in the ageing process. Nature 592, 695\u2013703 (2021).","journal-title":"Nature"},{"key":"2799_CR22","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1101\/gad.343129.120","volume":"34","author":"J Birch","year":"2020","unstructured":"Birch, J. & Gil, J. Senescence and the SASP: many therapeutic avenues. Genes Dev. 34, 1565\u20131576 (2020).","journal-title":"Genes Dev."},{"key":"2799_CR23","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.18632\/aging.204701","volume":"15","author":"P Samakkarnthai","year":"2023","unstructured":"Samakkarnthai, P. et al. In vitro and in vivo effects of zoledronic acid on senescence and senescence-associated secretory phenotype markers. Aging 15, 3331\u20133355 (2023).","journal-title":"Aging"},{"key":"2799_CR24","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/joim.13141","volume":"288","author":"JL Kirkland","year":"2020","unstructured":"Kirkland, J. L. & Tchkonia, T. Senolytic drugs: from discovery to translation. J. Intern. Med. 288, 518\u2013536 (2020).","journal-title":"J. Intern. Med."},{"key":"2799_CR25","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/nprot.2014.138","volume":"9","author":"R Jafari","year":"2014","unstructured":"Jafari, R. et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat. Protoc. 9, 2100\u20132122 (2014).","journal-title":"Nat. Protoc."},{"key":"2799_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22116-0","volume":"12","author":"J Candia","year":"2022","unstructured":"Candia, J., Daya, G. N., Tanaka, T., Ferrucci, L. & Walker, K. A. Assessment of variability in the plasma 7k SomaScan proteomics assay. Sci. Rep. 12, 17147 (2022).","journal-title":"Sci. Rep."},{"key":"2799_CR27","doi-asserted-by":"publisher","first-page":"890410","DOI":"10.3389\/fonc.2022.890410","volume":"12","author":"S Hernandez","year":"2022","unstructured":"Hernandez, S. et al. Challenges and Opportunities for Immunoprofiling Using a Spatial High-Plex Technology: The NanoString GeoMx(\u00ae) Digital Spatial Profiler. Front. Oncol. 12, 890410 (2022).","journal-title":"Front. Oncol."},{"key":"2799_CR28","doi-asserted-by":"publisher","first-page":"116289","DOI":"10.1016\/j.bone.2021.116289","volume":"156","author":"FH Ebetino","year":"2022","unstructured":"Ebetino, F. H. et al. Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use. Bone 156, 116289 (2022).","journal-title":"Bone"},{"key":"2799_CR29","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.3390\/molecules25112602","volume":"25","author":"JC Branco Santos","year":"2020","unstructured":"Branco Santos, J. C. et al. Bisphosphonate-Based Molecules as Potential New Antiparasitic Drugs. Molecules 25, 2602 (2020).","journal-title":"Molecules"},{"key":"2799_CR30","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/jdi.12944","volume":"10","author":"M Karimi Fard","year":"2019","unstructured":"Karimi Fard, M. et al. Alendronate improves fasting plasma glucose and insulin sensitivity, and decreases insulin resistance in prediabetic osteopenic postmenopausal women: A randomized triple-blind clinical trial. J. Diab Investig. 10, 731\u2013737 (2019).","journal-title":"J. Diab Investig."},{"key":"2799_CR31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/leu.2011.282","volume":"26","author":"ND Modi","year":"2012","unstructured":"Modi, N. D. & Lentzsch, S. Bisphosphonates as antimyeloma drugs. Leukemia 26, 589\u2013594 (2012).","journal-title":"Leukemia"},{"key":"2799_CR32","doi-asserted-by":"crossref","unstructured":"Djulbegovic, B. et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst. Rev. CD003188 (2001).","DOI":"10.1002\/14651858.CD003188"},{"key":"2799_CR33","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3390\/biomedicines10051146","volume":"10","author":"E Chiarella","year":"2022","unstructured":"Chiarella, E., Nistic\u00f2, C., Di Vito, A., Morrone, H. L. & Mesuraca, M. Targeting of Mevalonate-Isoprenoid Pathway in Acute Myeloid Leukemia Cells by Bisphosphonate Drugs. Biomedicines 10, 1146 (2022).","journal-title":"Biomedicines"},{"key":"2799_CR34","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1399-0012.2011.01527.x","volume":"26","author":"S Ganguly","year":"2012","unstructured":"Ganguly, S. et al. Prophylactic use of zoledronic acid to prevent early bone loss is safe and feasible in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Clin. Transplant. 26, 447\u2013453 (2012).","journal-title":"Clin. Transplant."},{"key":"2799_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2023.147338","volume":"866","author":"V Janakiraman","year":"2023","unstructured":"Janakiraman, V. et al. Rheumatoid arthritis treatment with zoledronic acid, a potential inhibitor of GWAS-derived pharmacogenetics STAT3 and IL2 targets. Gene 866, 147338 (2023).","journal-title":"Gene"},{"key":"2799_CR36","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1021\/acs.bioconjchem.7b00008","volume":"28","author":"H Lee","year":"2017","unstructured":"Lee, H., Bhang, S. H., Lee, J. H., Kim, H. & Hahn, S. K. Tocilizumab\u2013Alendronate Conjugate for Treatment of Rheumatoid Arthritis. Bioconjug. Chem. 28, 1084\u20131092 (2017).","journal-title":"Bioconjug. Chem."},{"key":"2799_CR37","doi-asserted-by":"publisher","first-page":"6921","DOI":"10.3390\/ijms23136921","volume":"23","author":"G Iolascon","year":"2022","unstructured":"Iolascon, G. & Moretti, A. The Rationale for Using Neridronate in Musculoskeletal Disorders: From Metabolic Bone Diseases to Musculoskeletal Pain. Int. J. Mol. Sci. 23, 6921 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2799_CR38","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1002\/1529-0131(200009)43:9<1951::AID-ANR5>3.0.CO;2-K","volume":"43","author":"P Barrera","year":"2000","unstructured":"Barrera, P. et al. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum. 43, 1951\u20131959 (2000).","journal-title":"Arthritis Rheum."},{"key":"2799_CR39","first-page":"114","volume":"30","author":"H Valleala","year":"2012","unstructured":"Valleala, H., Laasonen, L., Koivula, M.-K., Risteli, J. & Konttinen, Y. T. Effect of oral clodronate on structural damage and bone turnover in rheumatoid arthritis. Clin. Exp. Rheumatol. 30, 114\u2013117 (2012).","journal-title":"Clin. Exp. Rheumatol."},{"key":"2799_CR40","first-page":"23","volume":"84","author":"M Muratore","year":"2013","unstructured":"Muratore, M., Quarta, E. & Quarta, L. Intramuscular neridronate in patients with rheumatoid arthritis using corticosteroids: evaluation of treatment adherence in a randomized, open-label comparison with other bisphosphonates. Acta Biomed. 84, 23\u201329 (2013).","journal-title":"Acta Biomed."},{"key":"2799_CR41","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s13018-019-1492-3","volume":"14","author":"J Xie","year":"2019","unstructured":"Xie, J. et al. Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients. J. Orthop. Surg. 14, 421 (2019).","journal-title":"J. Orthop. Surg."},{"key":"2799_CR42","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.3899\/jrheum.080201","volume":"35","author":"M Soejima","year":"2008","unstructured":"Soejima, M. et al. Therapeutic effects of alendronate on bone erosion and atrophy in a patient with rheumatoid arthritis and hepatitis C virus infection. J. Rheumatol. 35, 2284\u20132286 (2008).","journal-title":"J. Rheumatol."},{"key":"2799_CR43","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00198-023-06781-z","volume":"34","author":"S-M Lin","year":"2023","unstructured":"Lin, S.-M. et al. Association between bisphosphonate use and stroke risk: a meta-analysis. Osteoporos. Int. 34, 1625\u20131636 (2023).","journal-title":"Osteoporos. Int."},{"key":"2799_CR44","doi-asserted-by":"publisher","first-page":"3511385","DOI":"10.1155\/2022\/3511385","volume":"2022","author":"Z Bo","year":"2022","unstructured":"Bo, Z. et al. Pharmacotherapies for Central Post-Stroke Pain: A Systematic Review and Network Meta-Analysis. Oxid. Med. Cell. Longev. 2022, 3511385 (2022).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"2799_CR45","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ahj.2012.10.023","volume":"165","author":"S Banai","year":"2013","unstructured":"Banai, S. et al. Targeted anti-inflammatory systemic therapy for restenosis: the Biorest Liposomal Alendronate with Stenting Study (BLAST)-a double blind, randomized clinical trial. Am. Heart J. 165, 234\u2013240.e1 (2013).","journal-title":"Am. Heart J."},{"key":"2799_CR46","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jconrel.2011.11.037","volume":"161","author":"D Gutman","year":"2012","unstructured":"Gutman, D. & Golomb, G. Liposomal alendronate for the treatment of restenosis. J. Control. Release 161, 619\u2013627 (2012).","journal-title":"J. Control. Release"},{"key":"2799_CR47","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s11914-020-00612-4","volume":"18","author":"EO Billington","year":"2020","unstructured":"Billington, E. O. & Reid, I. R. Benefits of Bisphosphonate Therapy: Beyond the Skeleton. Curr. Osteoporos. Rep. 18, 587\u2013596 (2020).","journal-title":"Curr. Osteoporos. Rep."},{"key":"2799_CR48","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/j.bcp.2010.08.015","volume":"80","author":"G-P Chen","year":"2010","unstructured":"Chen, G.-P. et al. Chronic inhibition of farnesyl pyrophosphate synthase improves endothelial function in spontaneously hypertensive rats. Biochem. Pharmacol. 80, 1684\u20131689 (2010).","journal-title":"Biochem. Pharmacol."},{"key":"2799_CR49","first-page":"47","volume":"5","author":"LL Santos","year":"2012","unstructured":"Santos, L. L., Cavalcanti, T. B. & Bandeira, F. A. Vascular effects of bisphosphonates-a systematic review. Clin. Med. Insights Endocrinol. Diab 5, 47\u201354 (2012).","journal-title":"Clin. Med. Insights Endocrinol. Diab"},{"key":"2799_CR50","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1749-6632.1999.tb07702.x","volume":"878","author":"O Teronen","year":"1999","unstructured":"Teronen, O. et al. MMP inhibition and downregulation by bisphosphonates. Ann. N. Y. Acad. Sci. 878, 453\u2013465 (1999).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2799_CR51","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2016.06.039","volume":"252","author":"G Kranenburg","year":"2016","unstructured":"Kranenburg, G. et al. Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis. Atherosclerosis 252, 106\u2013115 (2016).","journal-title":"Atherosclerosis"},{"key":"2799_CR52","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.2147\/CIA.S138002","volume":"12","author":"C Caffarelli","year":"2017","unstructured":"Caffarelli, C., Montagnani, A., Nuti, R. & Gonnelli, S. Bisphosphonates, atherosclerosis and vascular calcification: update and systematic review of clinical studies. Clin. Interv. Aging 12, 1819\u20131828 (2017).","journal-title":"Clin. Interv. Aging"},{"key":"2799_CR53","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/MPH.0b013e3181edb464","volume":"32","author":"DK Kuriyama","year":"2010","unstructured":"Kuriyama, D. K., McElligott, S. C., Glaser, D. W. & Thompson, K. S. Treatment of Gorham-Stout disease with zoledronic acid and interferon-\u03b1: a case report and literature review. J. Pediatr. Hematol. Oncol. 32, 579\u2013584 (2010).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"2799_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02433-6","volume":"18","author":"A Brufsky","year":"2020","unstructured":"Brufsky, A., Marti, J. L. G., Nasrazadani, A. & Lotze, M. T. Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection. J. Transl. Med. 18, 261 (2020).","journal-title":"J. Transl. Med."},{"key":"2799_CR55","doi-asserted-by":"publisher","first-page":"e79548","DOI":"10.7554\/eLife.79548","volume":"12","author":"J Thompson","year":"2023","unstructured":"Thompson, J. et al. Association between bisphosphonate use and COVID-19 related outcomes. Elife 12, e79548 (2023).","journal-title":"Elife"},{"key":"2799_CR56","doi-asserted-by":"publisher","first-page":"6869","DOI":"10.3390\/ijms22136869","volume":"22","author":"Z Mbese","year":"2021","unstructured":"Mbese, Z. & Aderibigbe, B. A. Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer. Int. J. Mol. Sci. 22, 6869 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2799_CR57","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.ejcts.2009.11.051","volume":"37","author":"J Nakajima","year":"2010","unstructured":"Nakajima, J. et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur. J. Cardio-Thorac. Surg. 37, 1191\u20131197 (2010).","journal-title":"Eur. J. Cardio-Thorac. Surg."},{"key":"2799_CR58","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3816\/CLC.2011.n.003","volume":"12","author":"R Mahtani","year":"2011","unstructured":"Mahtani, R., Khan, R. & Jahanzeb, M. The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer. Clin. Lung Cancer 12, 26\u201332 (2011).","journal-title":"Clin. Lung Cancer"},{"key":"2799_CR59","first-page":"2985","volume":"20","author":"MA Lopez-Olivo","year":"2012","unstructured":"Lopez-Olivo, M. A. et al. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Support. Care Cancer 20, 2985\u20132998 (2012).","journal-title":"Support. Care Cancer"},{"key":"2799_CR60","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022839","volume":"100","author":"M Li","year":"2021","unstructured":"Li, M., Zhong, M. & Guan, C. Bisphosphonates and risk of lung cancer: Protocol for a systematic review and meta-analysis. Med. (Baltim.) 100, e22839 (2021).","journal-title":"Med. (Baltim.)"},{"key":"2799_CR61","doi-asserted-by":"publisher","first-page":"1219250","DOI":"10.3389\/fimmu.2023.1219250","volume":"14","author":"M Sanz","year":"2023","unstructured":"Sanz, M. et al. Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1. Front. Immunol. 14, 1219250 (2023).","journal-title":"Front. Immunol."},{"key":"2799_CR62","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/MNH.0000000000000682","volume":"30","author":"M Prochaska","year":"2021","unstructured":"Prochaska, M. Bisphosphonates and management of kidney stones and bone disease. Curr. Opin. Nephrol. Hypertens. 30, 184\u2013189 (2021).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"2799_CR63","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00262-011-1049-8","volume":"60","author":"JM Lang","year":"2011","unstructured":"Lang, J. M. et al. Pilot trial of interleukin-2 and zoledronic acid to augment \u03b3\u03b4 T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol. Immunother. 60, 1447\u20131460 (2011).","journal-title":"Cancer Immunol. Immunother."},{"key":"2799_CR64","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.clgc.2014.07.002","volume":"13","author":"RJ Broom","year":"2015","unstructured":"Broom, R. J. et al. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial. Clin. Genitourin. Cancer 13, 50\u201358 (2015).","journal-title":"Clin. Genitourin. Cancer"},{"key":"2799_CR65","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3748\/wjg.v22.i3.906","volume":"22","author":"C Ang","year":"2016","unstructured":"Ang, C., Doyle, E. & Branch, A. Bisphosphonates as potential adjuvants for patients with cancers of the digestive system. World J. Gastroenterol. 22, 906\u2013916 (2016).","journal-title":"World J. Gastroenterol."},{"key":"2799_CR66","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2174\/187152012799014995","volume":"12","author":"F Saad","year":"2012","unstructured":"Saad, F. & Mulders, P. Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers. Anticancer Agents Med. Chem. 12, 129\u2013136 (2012).","journal-title":"Anticancer Agents Med. Chem."},{"key":"2799_CR67","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1021\/acs.molpharmaceut.5b00670","volume":"13","author":"AS Massey","year":"2016","unstructured":"Massey, A. S. et al. Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide. Rala. Mol. Pharm. 13, 1217\u20131228 (2016).","journal-title":"Rala. Mol. Pharm."},{"key":"2799_CR68","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejphar.2010.05.010","volume":"641","author":"K Iguchi","year":"2010","unstructured":"Iguchi, K., Tatsuda, Y., Usui, S. & Hirano, K. Pamidronate inhibits antiapoptotic bcl-2 expression through inhibition of the mevalonate pathway in prostate cancer PC-3 cells. Eur. J. Pharmacol. 641, 35\u201340 (2010).","journal-title":"Eur. J. Pharmacol."},{"key":"2799_CR69","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eururo.2003.12.012","volume":"45","author":"J-C Dumon","year":"2004","unstructured":"Dumon, J.-C., Journ\u00e9, F., Kheddoumi, N., Lagneaux, L. & Body, J.-J. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur. Urol. 45, 528\u2013529 (2004).","journal-title":"Eur. Urol."},{"key":"2799_CR70","doi-asserted-by":"publisher","first-page":"e2014","DOI":"10.1097\/MD.0000000000002014","volume":"94","author":"J Liu","year":"2015","unstructured":"Liu, J. et al. Bisphosphonates in the Treatment of Patients With Metastatic Breast, Lung, and Prostate Cancer: A Meta-Analysis. Med. (Baltim.) 94, e2014 (2015).","journal-title":"Med. (Baltim.)"},{"key":"2799_CR71","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00198-010-1353-8","volume":"22","author":"G Duque","year":"2011","unstructured":"Duque, G., Li, W., Adams, M., Xu, S. & Phipps, R. Effects of risedronate on bone marrow adipocytes in postmenopausal women. Osteoporos. Int. 22, 1547\u20131553 (2011).","journal-title":"Osteoporos. Int."},{"key":"2799_CR72","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.1210\/en.2014-1359","volume":"155","author":"G-W Li","year":"2014","unstructured":"Li, G.-W. et al. Influence of early zoledronic acid administration on bone marrow fat in ovariectomized rats. Endocrinology 155, 4731\u20134738 (2014).","journal-title":"Endocrinology"},{"key":"2799_CR73","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/CCO.0000000000000645","volume":"32","author":"L van der Heijden","year":"2020","unstructured":"van der Heijden, L., Dijkstra, S., van de Sande, M. & Gelderblom, H. Current concepts in the treatment of giant cell tumour of bone. Curr. Opin. Oncol. 32, 332\u2013338 (2020).","journal-title":"Curr. Opin. Oncol."},{"key":"2799_CR74","doi-asserted-by":"publisher","first-page":"107611","DOI":"10.1016\/j.pharmthera.2020.107611","volume":"214","author":"K-H Lu","year":"2020","unstructured":"Lu, K.-H., Lu, E. W.-H., Lin, C.-W., Yang, J.-S. & Yang, S.-F. New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma. Pharmacol. Ther. 214, 107611 (2020).","journal-title":"Pharmacol. Ther."},{"key":"2799_CR75","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1007\/s001250100008","volume":"44","author":"EB Jude","year":"2001","unstructured":"Jude, E. B. et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 44, 2032\u20132037 (2001).","journal-title":"Diabetologia"},{"key":"2799_CR76","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.pharep.2018.03.011","volume":"70","author":"S Zameer","year":"2018","unstructured":"Zameer, S., Najmi, A. K., Vohora, D. & Akhtar, M. Bisphosphonates: Future perspective for neurological disorders. Pharmacol. Rep. 70, 900\u2013907 (2018).","journal-title":"Pharmacol. Rep."},{"key":"2799_CR77","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fnmol.2020.00087","volume":"13","author":"R Seist","year":"2020","unstructured":"Seist, R. et al. Regeneration of Cochlear Synapses by Systemic Administration of a Bisphosphonate. Front. Mol. Neurosci. 13, 87 (2020).","journal-title":"Front. Mol. Neurosci."},{"key":"2799_CR78","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/jat.4160","volume":"41","author":"S Zameer","year":"2021","unstructured":"Zameer, S. et al. Alendronate reduces the cognitive and neurological disturbances induced by combined doses of d-galactose and aluminum chloride in mice. J. Appl. Toxicol. 41, 1779\u20131793 (2021).","journal-title":"J. Appl. Toxicol."},{"key":"2799_CR79","doi-asserted-by":"publisher","first-page":"4830","DOI":"10.1182\/blood.V104.11.4830.4830","volume":"104","author":"DV Vasconcellos","year":"2004","unstructured":"Vasconcellos, D. V. et al. Anti-Tumour Effect of Zoledronate in Cells from B Chronic Lymphoytic Leukemia and Low-Grade Lymphoma Patients. Blood 104, 4830 (2004).","journal-title":"Blood"},{"key":"2799_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-81","volume":"8","author":"JM Tuomela","year":"2008","unstructured":"Tuomela, J. M., Valta, M. P., V\u00e4\u00e4n\u00e4nen, K. & H\u00e4rk\u00f6nen, P. L. Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice. BMC Cancer 8, 81 (2008).","journal-title":"BMC Cancer"},{"key":"2799_CR81","volume":"10","author":"B O\u2019Carrigan","year":"2017","unstructured":"O\u2019Carrigan, B. et al. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst. Rev. 10, CD003474 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"2799_CR82","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1200\/JCO.2016.71.4337","volume":"35","author":"A Fournier","year":"2017","unstructured":"Fournier, A. et al. Use of Bisphosphonates and Risk of Breast Cancer in a French Cohort of Postmenopausal Women. J. Clin. Oncol. 35, 3230\u20133239 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2799_CR83","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00262-012-1368-4","volume":"62","author":"T Sugie","year":"2013","unstructured":"Sugie, T. et al. Zoledronic acid-induced expansion of \u03b3\u03b4 T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells. Cancer Immunol. Immunother. 62, 677\u2013687 (2013).","journal-title":"Cancer Immunol. Immunother."},{"key":"2799_CR84","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3109\/03009742.2015.1038300","volume":"44","author":"CC Mok","year":"2015","unstructured":"Mok, C. C., Li, O. C., Chan, K. L., Ho, L. Y. & Hui, P. K. Effect of golimumab and pamidronate on clinical efficacy and MRI inflammation in axial spondyloarthritis: a 48-week open randomized trial. Scand. J. Rheumatol. 44, 480\u2013486 (2015).","journal-title":"Scand. J. Rheumatol."},{"key":"2799_CR85","doi-asserted-by":"publisher","first-page":"12029","DOI":"10.1073\/pnas.1906713117","volume":"117","author":"MB Cubria","year":"2020","unstructured":"Cubria, M. B. et al. Evaluation of musculoskeletal phenotype of the G608G progeria mouse model with lonafarnib, pravastatin, and zoledronic acid as treatment groups. Proc. Natl. Acad. Sci. USA 117, 12029\u201312040 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2799_CR86","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1161\/CIRCULATIONAHA.116.022188","volume":"134","author":"LB Gordon","year":"2016","unstructured":"Gordon, L. B. et al. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome. Circulation 134, 114\u2013125 (2016).","journal-title":"Circulation"},{"key":"2799_CR87","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/jnci\/djac050","volume":"114","author":"KM Tuesley","year":"2022","unstructured":"Tuesley, K. M. et al. Nitrogen-based Bisphosphonate Use and Ovarian Cancer Risk in Women Aged 50 Years and Older. J. Natl. Cancer Inst. 114, 878\u2013884 (2022).","journal-title":"J. Natl. Cancer Inst."},{"key":"2799_CR88","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1159\/000323150","volume":"3","author":"A Shigemitsu","year":"2010","unstructured":"Shigemitsu, A., Furukawa, N., Koike, N. & Kobayashi, H. Endometrial cancer diagnosed by the presence of bone metastasis and treated with zoledronic Acid: a case report and review of the literature. Case Rep. Oncol. 3, 471\u2013476 (2010).","journal-title":"Case Rep. Oncol."},{"key":"2799_CR89","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ygyno.2018.06.012","volume":"150","author":"X Zhang","year":"2018","unstructured":"Zhang, X. et al. Risk reduction of endometrial and ovarian cancer after bisphosphonates use: A meta-analysis. Gynecol. Oncol. 150, 509\u2013514 (2018).","journal-title":"Gynecol. Oncol."},{"key":"2799_CR90","doi-asserted-by":"publisher","first-page":"E449","DOI":"10.1002\/ijc.27353","volume":"131","author":"V Lavou\u00e9","year":"2012","unstructured":"Lavou\u00e9, V. et al. Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of V\u03b39V\u03b42 T cells impaired by the prostaglandin E2 immunosuppressive factor: Implications for immunotherapy. Int. J. Cancer 131, E449\u2013E462 (2012).","journal-title":"Int. J. Cancer"},{"key":"2799_CR91","first-page":"6015","volume":"62","author":"K Sawada","year":"2002","unstructured":"Sawada, K. et al. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho. Cancer Res 62, 6015\u20136020 (2002).","journal-title":"Cancer Res"},{"key":"2799_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08649-9","volume":"7","author":"MI Abdullah","year":"2017","unstructured":"Abdullah, M. I., Abed, M. N. & Richardson, A. Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells. Sci. Rep. 7, 8090 (2017).","journal-title":"Sci. Rep."},{"key":"2799_CR93","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1002\/jcp.24929","volume":"230","author":"LM Coe","year":"2015","unstructured":"Coe, L. M., Tekalur, S. A., Shu, Y., Baumann, M. J. & McCabe, L. R. Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation. J. Cell. Physiol. 230, 1944\u20131953 (2015).","journal-title":"J. Cell. Physiol."},{"key":"2799_CR94","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3390\/jcm10050996","volume":"10","author":"AD Anastasilakis","year":"2021","unstructured":"Anastasilakis, A. D. et al. The Impact of Antiosteoporotic Drugs on Glucose Metabolism and Fracture Risk in Diabetes: Good or Bad News? J. Clin. Med. 10, 996 (2021).","journal-title":"J. Clin. Med."},{"key":"2799_CR95","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00198-022-06616-3","volume":"34","author":"P-W Chen","year":"2023","unstructured":"Chen, P.-W. et al. Association of bisphosphonates with diabetes risk and glycemic control: a meta-analysis. Osteoporos. Int. 34, 387\u2013397 (2023).","journal-title":"Osteoporos. Int."},{"key":"2799_CR96","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","volume":"379","author":"IR Reid","year":"2018","unstructured":"Reid, I. R. et al. Fracture Prevention with Zoledronate in Older Women with Osteopenia. N. Engl. J. Med. 379, 2407\u20132416 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2799_CR97","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1359\/jbmr.091009","volume":"25","author":"AJ Roelofs","year":"2010","unstructured":"Roelofs, A. J. et al. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J. Bone Miner. Res. 25, 606\u2013616 (2010).","journal-title":"J. Bone Miner. Res."},{"key":"2799_CR98","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/2159-8290.CD-14-0621","volume":"5","author":"S Junankar","year":"2015","unstructured":"Junankar, S. et al. Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer. Cancer Discov. 5, 35\u201342 (2015).","journal-title":"Cancer Discov."},{"key":"2799_CR99","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.72430","volume":"10","author":"MA Munoz","year":"2021","unstructured":"Munoz, M. A. et al. Bisphosphonate drugs have actions in the lung and inhibit the mevalonate pathway in alveolar macrophages. eLife 10, e72430 (2021).","journal-title":"eLife"},{"key":"2799_CR100","doi-asserted-by":"publisher","first-page":"34967","DOI":"10.1074\/jbc.274.49.34967","volume":"274","author":"AA Reszka","year":"1999","unstructured":"Reszka, A. A., Halasy-Nagy, J. M., Masarachia, P. J. & Rodan, G. A. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J. Biol. Chem. 274, 34967\u201334973 (1999).","journal-title":"J. Biol. Chem."},{"key":"2799_CR101","doi-asserted-by":"publisher","unstructured":"Feyertag, F. & Huber, K. V. M. TP-MAP - an Integrated Software Package for the Analysis of 1D and 2D Thermal Profiling Data. bioRxiv. Preprint at https:\/\/doi.org\/10.1101\/2021.02.22.432361 (2021).","DOI":"10.1101\/2021.02.22.432361"},{"key":"2799_CR102","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3390\/cells12081211","volume":"12","author":"A Qi","year":"2023","unstructured":"Qi, A. et al. Essential Protein PHB2 and Its Regulatory Mechanisms in Cancer. Cells 12, 1211 (2023).","journal-title":"Cells"},{"key":"2799_CR103","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.2174\/1568026619666190227222930","volume":"19","author":"Y Vijayan","year":"2019","unstructured":"Vijayan, Y., Lankadasari, M. B. & Harikumar, K. B. Acid Ceramidase: A Novel Therapeutic Target in Cancer. Curr. Top. Med. Chem. 19, 1512\u20131520 (2019).","journal-title":"Curr. Top. Med. Chem."},{"key":"2799_CR104","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3390\/ijms23031521","volume":"23","author":"VV Sobolev","year":"2022","unstructured":"Sobolev, V. V. et al. Role of the Transcription Factor FOSL1 in Organ Development and Tumorigenesis. Int. J. Mol. Sci. 23, 1521 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2799_CR105","first-page":"331","volume":"14","author":"B Liu","year":"2023","unstructured":"Liu, B., Ou, W.-C., Fang, L., Tian, C.-W. & Xiong, Y. Myocyte Enhancer Factor 2A Plays a Central Role in the Regulatory Networks of Cellular Physiopathology. Aging Dis. 14, 331\u2013349 (2023).","journal-title":"Aging Dis."},{"key":"2799_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/s12867-019-0125-z","volume":"20","author":"Y Xiong","year":"2019","unstructured":"Xiong, Y. et al. MEF2A alters the proliferation, inflammation-related gene expression profiles and its silencing induces cellular senescence in human coronary endothelial cells. BMC Mol. Biol. 20, 8 (2019).","journal-title":"BMC Mol. Biol."},{"key":"2799_CR107","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.18632\/aging.102015","volume":"11","author":"B Liu","year":"2019","unstructured":"Liu, B. et al. Myocyte enhancer factor 2A delays vascular endothelial cell senescence by activating the PI3K\/p-Akt\/SIRT1 pathway. Aging 11, 3768\u20133784 (2019).","journal-title":"Aging"},{"key":"2799_CR108","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"RGG Russell","year":"2008","unstructured":"Russell, R. G. G., Watts, N. B., Ebetino, F. H. & Rogers, M. J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos. Int. 19, 733\u2013759 (2008).","journal-title":"Osteoporos. Int."},{"key":"2799_CR109","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-1-4419-1050-9_2","volume":"658","author":"K Thompson","year":"2010","unstructured":"Thompson, K. et al. Activation of \u03b3\u03b4 T cells by bisphosphonates. Adv. Exp. Med. Biol. 658, 11\u201320 (2010).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2799_CR110","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJM199903043400914","volume":"340","author":"V Kunzmann","year":"1999","unstructured":"Kunzmann, V., Bauer, E. & Wilhelm, M. Gamma\/delta T-cell stimulation by pamidronate. N. Engl. J. Med. 340, 737\u2013738 (1999).","journal-title":"N. Engl. J. Med."},{"key":"2799_CR111","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/BF02556671","volume":"41","author":"S Adami","year":"1987","unstructured":"Adami, S. et al. The acute-phase response after bisphosphonate administration. Calcif. Tissue Int. 41, 326\u2013331 (1987).","journal-title":"Calcif. Tissue Int."},{"key":"2799_CR112","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s43587-021-00098-4","volume":"1","author":"Y Aman","year":"2021","unstructured":"Aman, Y. et al. Autophagy in healthy aging and disease. Nat. Aging 1, 634\u2013650 (2021).","journal-title":"Nat. Aging"},{"key":"2799_CR113","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.3390\/cancers11111812","volume":"11","author":"JY Oh","year":"2019","unstructured":"Oh, J. Y. et al. Synergistic Autophagy Effect of miR-212-3p in Zoledronic Acid-Treated In Vitro and Orthotopic In Vivo Models and in Patient-Derived Osteosarcoma Cells. Cancers 11, 1812 (2019).","journal-title":"Cancers"},{"key":"2799_CR114","doi-asserted-by":"publisher","first-page":"7203584","DOI":"10.1155\/2017\/7203584","volume":"2017","author":"J Zhu","year":"2017","unstructured":"Zhu, J. et al. Zoledronic Acid Regulates Autophagy and Induces Apoptosis in Colon Cancer Cell Line CT26. BioMed. Res. Int. 2017, 7203584 (2017).","journal-title":"BioMed. Res. Int."},{"key":"2799_CR115","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.lfs.2017.07.024","volume":"185","author":"Y Peng","year":"2017","unstructured":"Peng, Y. et al. M4IDP, a zoledronic acid derivative, induces G1 arrest, apoptosis and autophagy in HCT116 colon carcinoma cells via blocking PI3K\/Akt\/mTOR pathway. Life Sci. 185, 63\u201372 (2017).","journal-title":"Life Sci."},{"key":"2799_CR116","doi-asserted-by":"publisher","first-page":"11913","DOI":"10.1007\/s13277-014-2460-5","volume":"35","author":"I-T Wang","year":"2014","unstructured":"Wang, I.-T., Chou, S.-C. & Lin, Y.-C. Zoledronic acid induces apoptosis and autophagy in cervical cancer cells. Tumour Biol. 35, 11913\u201311920 (2014).","journal-title":"Tumour Biol."},{"key":"2799_CR117","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.juro.2010.11.045","volume":"185","author":"J-F Lin","year":"2011","unstructured":"Lin, J.-F. et al. Zoledronic acid induces autophagic cell death in human prostate cancer cells. J. Urol. 185, 1490\u20131496 (2011).","journal-title":"J. Urol."},{"key":"2799_CR118","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1124\/jpet.110.175521","volume":"337","author":"BM Wasko","year":"2011","unstructured":"Wasko, B. M., Dudakovic, A. & Hohl, R. J. Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate. J. Pharmacol. Exp. Ther. 337, 540\u2013546 (2011).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2799_CR119","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/stem.2255","volume":"34","author":"J Misra","year":"2016","unstructured":"Misra, J. et al. Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their Function. Stem Cells Dayt. 34, 756\u2013767 (2016).","journal-title":"Stem Cells Dayt."},{"key":"2799_CR120","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1093\/gerona\/glab172","volume":"77","author":"Z Chen","year":"2022","unstructured":"Chen, Z. et al. Zoledronate Extends Health Span and Survival via the Mevalonate Pathway in a FOXO-dependent Manner. J. Gerontol. A. Biol. Sci. Med. Sci. 77, 1494\u20131502 (2022).","journal-title":"J. Gerontol. A. Biol. Sci. Med. Sci."},{"key":"2799_CR121","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/s41591-022-01923-y","volume":"28","author":"S Chaib","year":"2022","unstructured":"Chaib, S., Tchkonia, T. & Kirkland, J. L. Cellular senescence and senolytics: the path to the clinic. Nat. Med. 28, 1556\u20131568 (2022).","journal-title":"Nat. Med."},{"key":"2799_CR122","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0960-9822(06)00261-2","volume":"7","author":"PJ Coates","year":"1997","unstructured":"Coates, P. J., Jamieson, D. J., Smart, K., Prescott, A. R. & Hall, P. A. The prohibitin family of mitochondrial proteins regulate replicative lifespan. Curr. Biol. 7, 607\u2013610 (1997).","journal-title":"Curr. Biol."},{"key":"2799_CR123","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nature08466","volume":"461","author":"M Artal-Sanz","year":"2009","unstructured":"Artal-Sanz, M. & Tavernarakis, N. Prohibitin couples diapause signalling to mitochondrial metabolism during ageing in C. elegans. Nature 461, 793\u2013797 (2009).","journal-title":"Nature"},{"key":"2799_CR124","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41401-022-00956-w","volume":"44","author":"L Wang","year":"2023","unstructured":"Wang, L. et al. Tetrahydroberberrubine retards heart aging in mice by promoting PHB2-mediated mitophagy. Acta Pharmacol. Sin. 44, 332\u2013344 (2023).","journal-title":"Acta Pharmacol. Sin."},{"key":"2799_CR125","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003021","volume":"8","author":"C Merkwirth","year":"2012","unstructured":"Merkwirth, C. et al. Loss of Prohibitin Membrane Scaffolds Impairs Mitochondrial Architecture and Leads to Tau Hyperphosphorylation and Neurodegeneration. PLoS Genet. 8, e1003021 (2012).","journal-title":"PLoS Genet."},{"key":"2799_CR126","doi-asserted-by":"publisher","first-page":"102321","DOI":"10.1016\/j.jchemneu.2023.102321","volume":"132","author":"H-G Bernstein","year":"2023","unstructured":"Bernstein, H.-G. et al. The many \u2018Neurofaces\u2019 of Prohibitins 1 and 2: Crucial for the healthy brain, dysregulated in numerous brain disorders. J. Chem. Neuroanat. 132, 102321 (2023).","journal-title":"J. Chem. Neuroanat."},{"key":"2799_CR127","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00726-020-02934-0","volume":"53","author":"Y Ma","year":"2021","unstructured":"Ma, Y. et al. Effects of long-term taurine supplementation on age-related changes in skeletal muscle function of Sprague-Dawley rats. Amino Acids 53, 159\u2013170 (2021).","journal-title":"Amino Acids"},{"key":"2799_CR128","doi-asserted-by":"publisher","first-page":"100710","DOI":"10.1016\/j.fbio.2020.100710","volume":"37","author":"L Munguia","year":"2020","unstructured":"Munguia, L. et al. Flavonoids from dark chocolate and (-)-epicatechin ameliorate high-fat diet-induced decreases in mobility and muscle damage in aging mice. Food Biosci. 37, 100710 (2020).","journal-title":"Food Biosci."},{"key":"2799_CR129","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd7695","volume":"13","author":"SJ Barker","year":"2021","unstructured":"Barker, S. J. et al. MEF2 is a key regulator of cognitive potential and confers resilience to neurodegeneration. Sci. Transl. Med. 13, eabd7695 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2799_CR130","doi-asserted-by":"publisher","first-page":"80","DOI":"10.14715\/cmb\/2024.70.1.11","volume":"70","author":"K Muhammad Sulaiman","year":"2024","unstructured":"Muhammad Sulaiman, K. A Study of transcription factor MEF2A gene polymorphisms in patients with coronary artery disease. Cell. Mol. Biol. 70, 80\u201386 (2024).","journal-title":"Cell. Mol. Biol."},{"key":"2799_CR131","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1126\/science.1088477","volume":"302","author":"L Wang","year":"2003","unstructured":"Wang, L., Fan, C., Topol, S. E., Topol, E. J. & Wang, Q. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science 302, 1578\u20131581 (2003).","journal-title":"Science"},{"key":"2799_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32552-1","volume":"13","author":"D Saul","year":"2022","unstructured":"Saul, D. et al. A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues. Nat. Commun. 13, 4827 (2022).","journal-title":"Nat. Commun."},{"key":"2799_CR133","doi-asserted-by":"publisher","first-page":"D537","DOI":"10.1093\/nar\/gki017","volume":"33","author":"JP de Magalh\u00e3es","year":"2005","unstructured":"de Magalh\u00e3es, J. P., Costa, J. & Toussaint, O. HAGR: the Human Ageing Genomic Resources. Nucleic Acids Res 33, D537\u2013D543 (2005).","journal-title":"Nucleic Acids Res"},{"key":"2799_CR134","doi-asserted-by":"publisher","first-page":"D1083","DOI":"10.1093\/nar\/gkx1042","volume":"46","author":"R Tacutu","year":"2018","unstructured":"Tacutu, R. et al. Human Ageing Genomic Resources: new and updated databases. Nucleic Acids Res 46, D1083\u2013D1090 (2018).","journal-title":"Nucleic Acids Res"},{"key":"2799_CR135","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"2799_CR136","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41586-018-0590-4","volume":"562","author":"N Schaum","year":"2018","unstructured":"Schaum, N. et al. Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris. Nature 562, 367\u2013372 (2018).","journal-title":"Nature"},{"key":"2799_CR137","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"2799_CR138","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-020-00267-2","volume":"15","author":"MS Vald\u00e9s-Tresanco","year":"2020","unstructured":"Vald\u00e9s-Tresanco, M. S., Vald\u00e9s-Tresanco, M. E., Valiente, P. A. & Moreno, E. AMDock: a versatile graphical tool for assisting molecular docking with Autodock Vina and Autodock4. Biol. Direct 15, 12 (2020).","journal-title":"Biol. Direct"},{"key":"2799_CR139","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris, G. M. et al. AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. J. Comput. Chem. 30, 2785\u20132791 (2009).","journal-title":"J. Comput. Chem."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02799-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02799-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02799-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:01:15Z","timestamp":1784070075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02799-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":139,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2799"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02799-x","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"9 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Human plasma samples used in this study were obtained from participants enrolled in the clinical trial entitled \u201cEfficacy of Zoledronate in fracture prevention in osteopenic postmenopausal women\u201d (Australian New Zealand Clinical Trials Registry: ACTRN12609000593235). The trial protocol was approved by the regional Health and Disability Ethics Committee (\n                      \n                      ). The study was conducted in full compliance with the Declaration of Helsinki. Written informed consent was obtained from all participants for the collection of plasma samples and their use in future research, including the present investigation. Animal studies were performed at the Mayo Clinic under protocols approved by the Institutional Animal Care and Use Committee (IACUC) and all experiments were performed in accordance with Mayo Clinic IACUC guidelines (A00001767-16-R22).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"277"}}